Edesa Biotech (EDSA) Reports FY 2021 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Edesa Biotech (EDSA) Reports FY 2021 Results

Edesa Biotech Reports Fiscal Year 2021 Results

December 28, 2021 4:16 PM EST

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business.

During the fiscal year, Edesa reported favorable interim results for both of the company's leading drug candidates, EB05 and EB01. EB05 is being developed as a potential treatment for ARDS, a life-threatening form of respiratory failure that accounts for approximately 10% of all ICU admissions (pre-pandemic) and is the leading cause of death among COVID-19 patients.... More